HUMA
Humacyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.60
+0.18%Margins
Gross margin
-666.8%
EBITDA margin
-3755.7%
EBIT margin
-5240.8%
Net margin
-4560.8%
FCF margin
-4599.7%
-309.4%
Return on equity
-70.1%
Return on assets
-114.1%
Return on invested capital
0.02x
Asset turnover
-$97.2M
Cash from operations
$0.29
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026